Delving into the Latest Updates on Fresenius Kabi Canada Ltd. with Synapse

AbstractBackgroundFor post marketed medicine, drug persistence could be used as an indication for effectiveness and safety in routine clinical care over time. Non-adherence and non-persistence to treatment are associated with disease flares and may lead to disease progression among patients with inflammatory bowel diseases (IBD) in real-life.AimsThe aim of this analysis was to explore drug persistence with an adalimumab biosimilar, Idacio, in IBD patients using the data collected by Fresenius Kabi patient support program (KabiCare) in Canada.MethodsPatients with IBD enrolled in KabiCare and received at least one dose of adalimumab biosimilar, Idacio, were followed up from February 2021 to September 2023 in Canada. Medication initiation date and stop date, disease types (Crohn’s disease [CD], and ulcerative colitis [UC]) and patient treatment (categorized by naïve to biologic,or switched from other biologics) were recorded in the database. The stop date was the date when KabiCare was informed that medication was discontinued. The patients continuing medication were censored at the maximal follow-up date of analysis, September 12, 2022. Log-rank tests were used for KM (Kaplan-Meier) plot comparison to examine if there were differences in medication adherence between CD and UC, and between naïve group vs. switch group by disease.ResultsThe study sample consisted of 1049 patients: 830 (79.1%) had CD, and 338 (32.2%) were in naïve group. KabiCare followed patients with CD for a median time of 512 days (interquartile range: 285-673 days; maximum: 895 days), and followed patients with UC for a median time of 492 days (interquartile range: 183-672 days; maximum: 925 days). At 800 days after starting the medicine, the drug persistence probability was similar for patients with CD and UC (At day-800: 76.6% vs. 67.6%, p=0.07). Among patients with CD, the drug persistence probability was higher in the switch group compared to naïve group (At day-800: 78.9% vs. 71.7%, p=0.0028). Among patients with UC, the drug persistence probably was similar in the switch group compared to naïve group (At day-800: 78.4% vs. 62.3%, p=0.34).ConclusionsThe drug persistence of adalimumab biosimilar, Idacio, was over 76% in patients with CD and over 67% in patients with UC 800 day after therapy initiation. Compared to patients in the naïve group, patients in the switch group were more likely to stay on adalimumab therapy.Funding AgenciesNone

100 项与 Fresenius Kabi Canada Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Fresenius Kabi Canada Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月25日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿达木单抗生物类似药(Merck Serono SA) ( TNF-α )	克罗恩病更多	批准上市
盐酸米托蒽醌 ( DNA x Top II )	乳腺癌更多	批准上市
L-亮氨酸/L-异亮氨酸/L-缬氨酸/L-醋酸赖氨酸/L-苏氨酸/L-色氨酸/L-甲硫氨酸/L-半胱氨酸/L-苯丙氨酸/L-酪氨酸/L-精氨酸/L-组氨酸/ L -丙氨酸/L-脯氨酸/L-丝氨酸/L-天冬氨酸/L-谷氨酸	营养不良更多	批准上市